drugset / Trial / NCT06455410
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of neoadjuvant GP chemotherapy plus adebrelimab versus neoadjuvant GP chemotherapy in treating high-risk locoregionally advanced nasopharyngeal carcinoma patients.
Timeline
- Start
- 2024-06-18
- Primary completion
- 2026-06-18
- Completion
- 2028-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |